ライフサイエンスコーパス: oxotremorine

1 of dystonia-like movement alterations after oxotremorine.

2 ne and again in the presence of serotonin or oxotremorine.

3 triatal injection of the cholinergic agonist oxotremorine.

4 arinic receptor-activated Kir3 currents with oxotremorine.

5 nge with the nonselective muscarinic agonist oxotremorine.

6 The nonsubtype-selective muscarinic agonist, oxotremorine (0.1-10 microm), inhibited potassium-stimul

7 s mimicked by a muscarinic receptor agonist (oxotremorine; 1 mum), and blunted by M1- (pirezenpine; 2

8 infusions of the muscarinic receptor agonist oxotremorine (10 ng/0.2 microliter per side) or saline.

9 Oxotremorine (a muscarinic agonist) and (-)butylthio[2.2

10 elated to the cerebral hyperemic response to oxotremorine, a muscarinic agonist that increases cerebr

11 /m4) receptor antagonists resulted in robust oxotremorine-activated Kir3 currents.

12 uscarinic agonist (arecoline, pilocarpine or oxotremorine), an acetylcholinesterase inhibitor (tacrin

13 Oxotremorine, an m2 muscarinic acetylcholine receptor (m

14 Prior to behavioral testing, oxotremorine, an M2 muscarinic receptor agonist that red

15 After systemic administration of oxotremorine, an unselective cholinergic agonist, Gnal(+

16 The standard muscarinic agonists oxotremorine and pilocarpine were both active in these t

17 ter, the effects of intraseptal scopolamine, oxotremorine, and muscimol were tested in a T-maze alter

18 mpletely blocked AMPH-stimulated SP mRNA and oxotremorine at 8.1 mM blocked AMPH-stimulated PPD mRNA.

19 mine into the dorsal striatum augmented, and oxotremorine attenuated, AMPH (2.5 mg/kg, i.p.)-stimulat

20 ts, whereas the muscarinic receptor agonist, oxotremorine, attenuates behaviors (locomotion and stere

21 ntrast, systemic scopolamine blocks, whereas oxotremorine augments, AMPH-stimulated preproenkephalin

22 However, both concentrations of oxotremorine completely blocked AMPH-stimulated SP mRNA

23 activation of M2 receptors in the pIC using oxotremorine completely reversed oxaliplatin-induced mec

24 Both serotonin and oxotremorine depolarize and excite isolated individual G

25 Intrastriatal infusion of 1.6 or 8.1 mM oxotremorine did not alter basal levels of striatal PPD

26 ese effects by administering scopolamine and oxotremorine directly into the striatum and assessing th

27 Serotonin and oxotremorine each increased the size of the parameter re

28 the following parameters were examined: (1) oxotremorine-enhanced striatal dopamine release (OX-K+-E

29 euronal and behavioral parameters including: oxotremorine enhancement of K(+)-evoked release of dopam

30 or, is potent (IC50 = 0.45 nM) in inhibiting oxotremorine-evoked [(3)H]DA release from rat striatal s

31 ppocampal infusions of a 1 microgram dose of oxotremorine exhibited significant deficits in freezing

32 Importantly, oxotremorine had no significant effects on ultrasound em

33 l muscarinic agonists, such as muscarine and oxotremorine, had higher affinity versus oxotremorine-M

34 Oxotremorine impaired accuracy similarly in control and

35 Thus, effects of oxotremorine in the hippocampal dentate gyrus do not pro

36 These oxotremorine-induced abnormalities in Gnal(+/-) mice wer

37 ceptors in brains from GRK5-KO mice resisted oxotremorine-induced desensitization, as assessed by oxo

38 havioral deficits in freezing may reflect an oxotremorine-induced disruption of hippocampal cholinerg

39 , the BF-saporin rats were hypersensitive to oxotremorine-induced hypothermia and demonstrated an inc

40 alities in Gnal(+/-) mice were replicated by oxotremorine infusion into the striatum, but not into th

41 the non-subtype-selective muscarinic agonist oxotremorine led to concentration-dependent increases in

42 with the largest cooperativity observed for oxotremorine M (Oxo-M) LY2119620.

43 ensitive to 100 microm Cd(2+) and 2.5 microm oxotremorine M (oxo-M), a muscarinic agonist, and fully

44 nergic agonist, and reduced 63% by 10 microM oxotremorine M (Oxo-M), a muscarinic agonist.

45 Blockade of M currents by oxotremorine M or linopirdine prevented the depolarizing

46 acetylcholine receptors (i.e. application of oxotremorine M to PTX-treated neurons) failed to elicit

47 Using the mAChR agonist Oxo M (oxotremorine M), we identified a GAR-3(mAChR)-G alpha(q)

48 The mAChR agonist oxotremorine-M (3-10 microM) dose-dependently decreased

49 efore compared the effects of bradykinin and oxotremorine-M (a muscarinic agonist) on membrane PIP(2)

50 ave demonstrated that the muscarinic agonist oxotremorine-m (oxo-m) blocks the induction of presynapt

51 nts were modulated by the muscarinic agonist oxotremorine-M (oxo-M) in a manner having all of the cha

52 bation of cells with the cholinergic agonist oxotremorine-M (Oxo-M) induced an approximately 6-fold i

53 Effects of a muscarinic receptor agonist oxotremorine-M (oxo-M) on bladder afferent nerve (BAN) a

54 Stimulation of M1 receptors by 10 microM oxotremorine-M (Oxo-M) strongly reduced (to 0-10%) curre

55 behavioral responsiveness to challenge with oxotremorine-M (Oxo-M), a nonselective muscarinic acetyl

56 oth were inhibited by 1 mM Ba2+ or 10 microM oxotremorine-M (Oxo-M).

57 Oxotremorine-M (OXO-M; 10 microM) produced a reversible

58 Furthermore, oxotremorine-M also dose-dependently increased the frequ

59 Oxotremorine-M also increased the sEPSC frequency in app

60 he magnitude of the full muscarinic agonists oxotremorine-M and cis-dioxolane.

61 eta-Acetoxynortropane had K(i) values versus oxotremorine-M binding at m(1)-, m(2)-, and m(4)-recepto

62 and oxotremorine, had higher affinity versus oxotremorine-M binding compared to quinuclidinyl benzila

63 loxy(nor)tropanes had higher affinity versus oxotremorine-M binding compared to quinuclidinyl benzila

64 ransfected m(3)-receptors, since significant oxotremorine-M binding could not be detected.

65 M4 subtype-preferring antagonist himbacine, oxotremorine-M caused a large increase in the sIPSC freq

66 prised to find that in M2/M4 double-KO mice, oxotremorine-M consistently increased the frequency of s

67 In wild-type mice, mAChR activation with oxotremorine-M decreased the amplitude of monosynaptic E

68 On the other hand, 1-10 microm oxotremorine-M dose-dependently increased the frequency

69 In M5 single-KO mice, oxotremorine-M failed to potentiate evoked EPSCs, and it

70 I mGluRs eliminated the inhibitory effect of oxotremorine-M in M2/M4 double-KO mice.

71 4129 did not block the stimulatory effect of oxotremorine-M in the majority of neurons from WT mice.

72 e-M or potentiated the stimulatory effect of oxotremorine-M in WT mice.

73 Strikingly, in M(5)-single KO mice, oxotremorine-M increased sEPSCs in only 26.3% neurons, a

74 The mAChR agonist oxotremorine-M increased the frequency of glutamatergic

75 In M2/M4 double-KO mice, oxotremorine-M inhibited monosynaptic EPSCs in significa

76 mice, but not M(2)- or M(4)-single KO mice, oxotremorine-M inhibited sEPSCs in significantly fewer n

77 , the inhibitory and potentiating effects of oxotremorine-M on EPSCs in M3 single-KO and M1/M3 double

78 Surprisingly, the effect of oxotremorine-M on sIPSCs was largely attenuated at a hig

79 t 4-DAMP abolished the stimulatory effect of oxotremorine-M on sIPSCs.

80 P55845 potentiated the stimulatory effect of oxotremorine-M on sIPSCs.

81 similarly reduced the potentiating effect of oxotremorine-M on sIPSCs.

82 e either attenuated the inhibitory effect of oxotremorine-M or potentiated the stimulatory effect of

83 Oxotremorine-M pretreatment protected cells from H(2)O(2

84 In M3 KO and M1/M3 double-KO mice, oxotremorine-M produced a consistent decrease in the fre

85 In M2 or M4 single-KO mice, oxotremorine-M produced a variable effect on sIPSCs; it

86 The mAChR agonist oxotremorine-M significantly increased the frequency of

87 inositol metabolism, but mutant A212E caused oxotremorine-M to become a weak partial agonist compared

88 y blocked the binding of [(3)H]NMS and [(3)H]oxotremorine-M to M2 receptors with Hill coefficients ne

89 ial Bax accumulation, also was attenuated by oxotremorine-M treatment after treatment with H(2)O(2) o

90 The inhibitory effect of oxotremorine-M was attenuated by the M2/M4 antagonist hi

91 st (quinuclidinyl benzilate) and an agonist (oxotremorine-M) at sites on human m(1)-, m(2)-, m(3)-, a

92 At low concentrations (e.g. 0.1-1 microM oxotremorine-M), 'burst-mode' activity comprised regular

93 ressive decrease in the apparent affinity of oxotremorine-M).

94 Pretreatment with oxotremorine-M, a selective agonist of muscarinic recept

95 arter of the reduction in PIP(2) produced by oxotremorine-M, but equal reduction when PIP(2) synthesi

96 ent with the nonselective muscarinic agonist oxotremorine-M, M2, and M4 receptors underwent significa

97 c receptors were stimulated with the agonist oxotremorine-M, several previously described currents we

98 gonists, acetylcholine (ACh), carbachol, and oxotremorine-M, while significantly increasing the maxim

99 Oxotremorine-M-induced activation of AP-1 was 40--53% lo

100 in combination with the M2 receptor agonist oxotremorine-M.

101 gnificantly reduced the inhibitory effect of oxotremorine-M.

102 of N-[(3)H]methylscopolamine by the agonist oxotremorine-M.

103 entiation of AMPK phosphorylation induced by oxotremorine-M.

104 nhibitor dephostatin prevented inhibition by oxotremorine-M.

105 Strikingly, oxotremorine-mediated potentiation of stimulated striata

106 The muscarinic agonist oxotremorine methiodide (oxo-M) stimulated PLC in a dose

107 lation by the muscarinic cholinergic agonist oxotremorine methiodide (oxo-M) was examined in sympathe

108 he NAcc with the muscarinic receptor agonist oxotremorine methiodide (OXO: 0.1, 0.3 or 1 nmol/side),

109 avesical administration of the mAChR agonist oxotremorine methiodide (OxoM) elicited concentration-de

110 er, enhancement and inhibition of current by oxotremorine methiodide mimics modulation observed with

111 Responses to Oxo-M [oxotremorine methiodide N,N,N,-trimethyl-4-(2-oxo-1-pyrr

112 athway, we found that the muscarinic agonist oxotremorine methiodide not only inhibits currents at po

113 The muscarinic agonist oxotremorine methiodide produced a dose-dependent reduct

114 ceptive (hot plate test) effects of ethanol, oxotremorine, nicotine, baclofen, clonidine, and the can

115 inic acetylcholine receptor (mAChR) agonist, oxotremorine, or the cholinesterase inhibitor, neostigmi

116 The animals received CHP, 25 mg/kg, p.o., or oxotremorine (OX), 0.2 mg/kg, s.c.

117 usions of the muscarinic cholinergic agonist oxotremorine (OXO) immediately after either context trai

118 ) currents are regulated in a slow manner by oxotremorine (oxo-M) and angiotensin II in rat sympathet

119 The muscarinic agonist oxotremorine restores the plateau potential in B31/B32 a

120 n-selective muscarinic agonists pilocarpine, oxotremorine, RS-86, S-aceclidine, but not the less acti

121 The nonselective muscarinic agonist oxotremorine showed reduced analgesic potency in M(2) re

122 d that the two CMI compounds, in contrast to oxotremorine, showed >6-fold higher affinity for M(4) th

123 rine-induced desensitization, as assessed by oxotremorine-stimulated [5S]GTPgammaS binding.

124 Both concentrations of oxotremorine tended to augment basal and AMPH-stimulated

125 icacy, from the low-efficacy pilocarpine and oxotremorine to high-efficacy acetylcholine.

126 Untreated and oxotremorine-treated Gnal(+/-) mice provide a model of p

127 lts also provide evidence that untreated and oxotremorine-treated Gnal-haplodeficient mice are powerf

128 In contrast, oxotremorine-treated rats had a stronger memory for the

129 The antinociceptive effect of oxotremorine was also potentiated and prolonged.

130 age increase in LD-CBF signal in response to oxotremorine was similar for both groups (SHR, 64%+/-22%

131 owmetry (LD-CBF), in response to intravenous oxotremorine, was measured in one cohort of rats to esti